Secondary analysis of radiation therapy oncology group study (RTOG) 9310: An intergroup phase II combined modality treatment of primary central nervous system lymphoma Academic Article uri icon

Overview

MeSH Major

  • Brain Neoplasms
  • Lymphoma

abstract

  • Although the HFX schedule represented a 25% reduction in biologically effective tumor dose in comparison, PFS and overall survival were not significantly affected. The HFX regimen delayed but did not eliminate severe neurotoxicity from chemoradiation in PCNSL patients.

publication date

  • September 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s11060-004-6596-9

PubMed ID

  • 16193393

Additional Document Info

start page

  • 201

end page

  • 5

volume

  • 74

number

  • 2